-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The United States Pharmacopeia (USP) released a drug supply map on March 16, designed to build visibility into the supply chain on pharmaceuticals and identify which APIs used in pharmaceuticals are prone to shortages
.
USP Map uses information from more than 40 datasets and 250 million data points from public and private sources to identify global manufacturing sites and quantify the risk and resilience of upstream pharmaceutical supply chains
.
These data are then supplemented with risk driver information, such as price, manufacturing location, chemical information, dosage form, and quality, to predict the risk of drug shortages
Vimala Raghavendran, director of USP's Center for Drug Supply Chains, said, "As the U.
S.
considers legislation to improve supply chain resiliency, insights from drug supply maps can provide greater visibility to aid decision-making
.
"
USP said its Drug Supply Vulnerability Insights series of work will examine the global distribution of APIs and the risks associated with specific drug classes, ranging from widely used drugs such as antimicrobials and statins to those urgently needed in small populations such as pediatric oncology drugs )
.
Future research findings will identify potential supply chain risks that could impact the supply of critical medicines
USP CEO Ronald T.
Piervincenzi noted, "USP's Drug Supply Map is an innovative early warning system that helps identify APIs and finished drug products that are at risk of shortages, so suppliers, drugmakers and governments can take action to help prevent shortages
.
"
USP's drug supply map shows that India remains unquestionably the largest supplier of APIs to the US, with 183 factories producing 10 or more US-approved API products and 114 factories producing 30 or more US-approved APIs
.
The EU is the second largest supplying region
In addition, USP also said that the upcoming USP Congress will discuss the Drug Supply Map to identify specific solutions to improve supply chain resilience, make recommendations to improve the continuous readiness cycle, including the impact on national inventories, and strengthen the relationship between supply chain partners.
